Covalent Modifiers

SEPTEMBER 9, 2023

3c05161 The stabilization of protein–protein interactions (PPIs) has emerged as a promising strategy in chemical biology and drug discovery. Here, we show the structure-based optimization of the nonselective fragment toward selective and highly potent small-molecule stabilizers of the 14-3-3σ/ERα complex.

Small Molecule 79

Small Molecule Biophysical Assays Production Drugs 79

Covalent Modifiers

FEBRUARY 1, 2024

link] Proteins labelled site-specifically with small molecules are valuable assets for chemical biology and drug development. Nat Commun 15 , 859 (2024). The unique reactivity profile of the 1,2-aminothiol moiety of N -terminal cysteines ( N -Cys) of proteins renders it highly attractive for regioselective protein labelling.

Biophysical Assays 79

Biophysical Assays Small Molecule Drug Development Production 79

Sygnature Discovery

JUNE 17, 2024

At Sygnature Discovery, we see biophysics as a core component of drug discovery projects, which can generate data throughout the pipeline. This wealth of experience supports our broader team of over 20 scientists, each trained in at least one biophysical technology.

Biophysical Assays 52

Biophysical Assays Screening Hits Assay Development Fragment Screening 52

Drug Target Review

NOVEMBER 1, 2023

Could you provide an overview of your research on target directed cancer drug discovery, particularly your focus on protein lagging interactions. I work in the Centre for Cancer Drug Discovery (CCDD) at The Institute of Cancer Research in London, which is an academic drug discovery centre. 2013) 56, 2059-2073.

Fragment Screening 96

Fragment Screening Biochemical Assays Small Molecule Biophysical Assays 96